Skip to content

ELASMOGEN

discovering and developing soloMERs for the treatment of auto-immune mediated, inflammatory diseases

ELASMOGEN
  • about
    • the team
    • the board
    • investors
  • soloMER technology
    • discovery platform
    • product development options
  • pipeline
    • auto-Immune / anti-Inflammatory
    • oncology
    • NDURE programme
  • partners
    • licensing
    • partnerships and collaborations
  • news
    • press release
    • publications
    • events
  • contact
Press release

Press release

  • Home
  • News
  • Press release
  • Press release
  • Publications
  • Events

News archives

  • January 2021
  • December 2020
  • July 2020
  • May 2020
  • April 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • July 2019
  • May 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • May 2018
  • January 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • July 2016
  • March 2016

Elasmogen announces a panel of novel, potent, anti-Covid-19 therapeutic candidates identified through collaboration with U.S. research partners | 25.01.2021

At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021: Aberdeen, Scotland:  Elasmogen Ltd, the pioneering biopharmaceutical company leading the development of VNAR and soloMERTM biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially […]

Elasmogen announces grants of 2 new VNAR and soloMER patent families | 09.12.2020

New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland:  Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announces a significant development in its comprehensive intellectual property position as two new patent families go to grant in multiple territories.  These […]

Elasmogen wins two grants worth £374,000 | 08.07.2020

New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020:  Aberdeen drug discovery pioneer, Elasmogen Ltd has won two new grants worth £374,000 to support programs for COVID-19 and oncology.  In April 2020 Elasmogen secured £143,000 from Scottish Government to use their drug discovery platform to accelerate […]

Intract Pharma and Elasmogen Ltd announce collaboration to discover and develop novel, orally-delivered protein therapeutics | 05.05.2020

Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel orally-delivered protein therapeutics (biologics), incorporating proprietary technologies developed by each of the partners. The collaboration combines Elasmogen’s soloMER™ technology, small (11 kDa) single-chain  binding domains that can be rapidly re-formatted to generate super-neutralizers (bivalent, […]

Elasmogen Ltd to deploy their soloMER technology platform to develop tools to combat COVID-19 | 29.04.2020

29th April 2020; Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) are to collaborate with the University of Aberdeen as a partner on a Scottish Government research award of almost £1 M to tackle COVID-19.    Current diagnostic testing for COVID-19 so called RT-PCR for infectious agents, whilst accurate is complex to perform, suited to centralised laboratories, takes […]

Elasmogen featured in Biotechnology and Biological Sciences Research Council Spinout report | 26.02.2020

Elasmogen has been featured in BBSRC’s report highlighting a few spinout companies that exemplify BBSRC investments in research.

Elasmogen nominated for Innovative Collaboration award with Almac Discovery | 24.01.2020

Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration award, sponsored by @MarksClerkScot are announced! They are @ElasmogenLtd , @iCAIRD_Scot , and @MedtronicUK . Find out who wins at #ScotLiSciAwards on 19 March – tickets available at https://t.co/z5f5tnBLNS pic.twitter.com/9Q7SOYezme — LifeScienceAwardScot […]

Elasmogen Secures £2 M Funding | 13.01.2020

Funding from Deepbridge Capital will support development of next generation biologics January 10th 2020: Aberdeen, Scotland:  Elasmogen Ltd, the biopharmaceutical company leading the development of soloMERTM biologics, today announced it has secured follow-on equity investment from Deepbridge Capital totalling £2 M, taking Deepbridge’s total investment in Elasmogen to £3.15 M.  The funding will be used […]

Elasmogen technology featured in The Times news | 13.12.2019

We are delighted that The Times has featured Elasmogen in an article titled ‘Ruthless killers? Shark antibodies are latest weapon in fight against cancer‘.

Elasmogen featured in CONVERGE podcast | 19.11.2019

Elasmogen’s CEO, Caroline Barelle is featured in Converge’s podcast where she discusses her business journey.

ELASMOGEN Copyright 2021

Liberty Building | Foresterhill Health Campus | Aberdeen | AB25 2ZP

  • info@elasmogen.com
  • twitter
  • linkedin